Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
10.90
-0.15 (-1.36%)
Nov 20, 2024, 4:00 PM EST - Market closed
Avalo Therapeutics Employees
Avalo Therapeutics had 19 employees as of December 31, 2023. The number of employees decreased by 1 or -5.00% compared to the previous year.
Employees
19
Change (1Y)
-1
Growth (1Y)
-5.00%
Revenue / Employee
$43,158
Profits / Employee
-$428,158
Market Cap
122.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 183 |
| Repare Therapeutics | 179 |
| Zomedica | 144 |
| TriSalus Life Sciences | 112 |
| Cabaletta Bio | 103 |
| Zentek | 24 |
| Outlook Therapeutics | 24 |
| Context Therapeutics | 5 |
AVTX News
- 9 days ago - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants - GlobeNewsWire
- 10 days ago - Avalo Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewsWire
- 5 months ago - Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - GlobeNewsWire
- 5 months ago - Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit - GlobeNewsWire
- 6 months ago - Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire